Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis
Australian study (n=180) found that the institutional cost per patient episode was lower with home ceftriaxone vs inpatient flucloxacillin (AUS$1965 vs $3775). As the QALY improvement was also greater with cetriaxone, cost-effectiveness analysis was redundant.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
More News: Australia Health | Ceftriaxone | Cellulitis | Children | Health | Hospitals | Rocephin | Study